The Most Politically Supervised Field in Medicine.
Regulatory strategy for analgesia — where an epidemic rewrote the rules and a new drug must prove it works and that it will not be abused.
No Other Field Carries This Much Regulatory Inheritance.
The opioid epidemic did not merely tighten analgesic regulation — it restructured it. Abuse-deterrent formulation guidance, mandatory REMS across the class, DEA scheduling entangled with FDA approval, prescriber education requirements, and a public and political scrutiny that reaches individual approval decisions. A pain program is reviewed by an agency that has been held responsible for the last one.
The consequence is that efficacy is necessary and nowhere near sufficient. Human abuse potential studies, a scheduling recommendation, a REMS design, and a promotional posture are all part of the approval — not follow-on work. We build analgesic programs that answer the abuse question as rigorously as the pain question, because the agency will.
Abuse potential, scheduling, and REMS are part of the approval — not follow-on work for after the label.
An Analgesic Approval Has Four Gates, Not One.
Pain programs are judged on efficacy, on abuse liability, on scheduling, and on risk management — sequentially and by different bodies. Any one of them can stop the product.
Approval
Efficacy, abuse potential, scheduling, and REMS — each assessed separately, each capable of ending the program.
Efficacy
A pain endpoint with a placebo response that regularly exceeds fifty percent, enrichment designs the division may or may not accept, and chronic-pain trials that struggle to retain patients.
Abuse Potential
Human abuse potential studies in recreational users, plus the eight-factor analysis that feeds the scheduling recommendation. A separate science with its own experts.
Scheduling & REMS
A DEA scheduling process that follows FDA approval and gates launch, and a REMS whose design shapes the product's entire commercial reality.
Pain Is Treated by Drugs, Devices, and Procedures — All Regulated Differently.
The field spans scheduled molecules, implanted stimulators, injectables, and software — competing for the same patient under different rules.
Novel Analgesics
Sodium-channel blockers and other non-addictive mechanisms — the field's most valuable regulatory position if the abuse package is airtight.
Opioid Analgesics
Abuse-deterrent formulations, class-wide REMS, and an approval environment shaped by an epidemic and its litigation.
Neuromodulation
Spinal cord and peripheral nerve stimulators — Class III PMA devices where sham-control design is the central methodological fight.
Interventional Pain
Injectables and ablation systems, frequently combination products, where the procedure and the product are hard to separate.
Behavioural & Digital
Prescription digital therapeutics for chronic pain, where the blinding problem is unsolved and engagement decays.
Acute & Peri-operative
Where the opioid-sparing claim lives, and where a clean non-opioid win has the clearest commercial and policy path.
Half the effect, in the control arm, before pharmacology. Design margin in pain is thin by default.
Pain Is a Symptom, and the Placebo Response Is Enormous.
Pain trials fight a placebo response that routinely reaches half the treatment effect and has been rising for decades in some indications. Add high dropout in chronic pain, rescue medication confounding the read, and a subjective primary endpoint, and the design margin is thin before the pharmacology is even considered.
Enrichment designs help and carry their own cost — a randomised withdrawal or enriched enrolment design can produce a cleaner signal and a narrower label, and the division does not accept them automatically. We choose the design against the label we intend to earn, and agree it before the trial that has to deliver it.
Every Analgesic Is Reviewed in the Shadow of the Last Decade.
This is the one field where the regulator's own institutional history is a live factor in your review.
Efficacy, abuse potential, scheduling, and REMS. They are assessed separately and any one of them can end the program.
placebo response is routine in pain trials, and rising in some indications — which is what the powering has to survive.
is now an explicit FDA public health priority. A genuinely non-addictive mechanism escapes scheduling and the class REMS entirely.
Six Failure Modes We Are Brought In to Prevent.
The pharmacology is rarely the reason. The abuse package and the design are.
Abuse liability underestimated
Reaching the NDA without a human abuse potential program, and stopping while the eight-factor analysis is assembled from nothing.
Placebo response ignored
Powering a chronic pain trial on assumptions that a modern placebo arm will demolish.
Enrichment unagreed
Running a randomised withdrawal design the division has not accepted for the claim, and earning a label nobody wanted.
Scheduling forgotten
Treating DEA scheduling as an administrative step after approval rather than a gate that delays launch by months.
REMS designed late
Bolting a risk management program on at the end, and accepting restrictions that make the product commercially unviable.
Sham control missing
A neuromodulation trial without a credible sham, in a field where the placebo effect of an implanted device is well documented.
Pain Regulatory Leadership Built for the Post-Epidemic Agency.
Our pain leads have run human abuse potential programs, negotiated REMS designs, and carried both non-opioid analgesics and neuromodulation devices to approval.
"In pain, proving the drug works is the part sponsors plan for. Proving it will not be abused — and surviving the placebo arm — is what actually decides the program."
The discipline we bring across non-opioid analgesics, opioids, neuromodulation, and interventional pain.
Developing an Analgesic? The Abuse Package Is Not a Late Deliverable.
Bring senior pain regulatory leadership in while the design, the abuse strategy, and the scheduling path can still be shaped.
Senior-led. Embedded in your team. No junior hand-offs.